Protective Effects of Statin and Angiotensin Receptor Blocker in a Rat Model of Doxorubicin- and Trastuzumab-Induced Cardiomyopathy

Receptor Blocker ◽

Protective Effects ◽

Protective effects of angiotensin-(1-7) administrated with an angiotensin-receptor blocker in a rat model of chronic kidney disease

Nephrology ◽

10.1111/nep.12146 ◽

2013 ◽

Vol 18 (12) ◽

pp. 761-769 ◽

Cited By ~ 12

Author(s):

Chengyan Xu ◽

Wei Ding ◽

Minmin Zhang ◽

Yong Gu

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Rat Model ◽

Receptor Blocker ◽

Protective Effects ◽

Long-term protective effects of the angiotensin-receptor blocker telmisartan on epirubucin-induced inflammation, oxidative stress, and myocardial dysfunction.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.9030 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 9030-9030

Author(s):

G. Mantovani ◽

C. Madeddu ◽

M. Dessi' ◽

E. Massa ◽

G. Antoni ◽

...

Keyword(s):

Oxidative Stress ◽

Myocardial Dysfunction ◽

Receptor Blocker ◽

Protective Effects ◽

Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction

Experimental and Therapeutic Medicine ◽

10.3892/etm.2011.305 ◽

2011 ◽

Vol 2 (5) ◽

pp. 1003-1009 ◽

Cited By ~ 33

Author(s):

MARIELE DESSÌ ◽

ALESSANDRA PIRAS ◽

CLELIA MADEDDU ◽

CHRISTIAN CADEDDU ◽

MARTINO DEIDDA ◽

...

Keyword(s):

Oxidative Stress ◽

Myocardial Dysfunction ◽

Receptor Blocker ◽

Protective Effects ◽

1261 POSTER Long-term Protective Effects of the Angiotensin Receptor Blocker Telmisartan on Epirubicin-induced Inflammation, Oxidative Stress and Myocardial Dysfunction

European Journal of Cancer ◽

10.1016/s0959-8049(11)70873-5 ◽

2011 ◽

Vol 47 ◽

pp. S163

Author(s):

G. Mantovani ◽

C. Madeddu ◽

A. Piras ◽

M. Dessi ◽

C. Cadeddu ◽

...

Keyword(s):

Oxidative Stress ◽

Myocardial Dysfunction ◽

Receptor Blocker ◽

Protective Effects ◽

Tu1656 THE ANGIOTENSIN RECEPTOR BLOCKER VALSARTAN ALLEVIATES THE INCREASED INTRAHEPATIC VASCULAR RESISTANCE AND DECREASES LIVER DAMAGE IN A RAT MODEL OF SEVERE STEATOSIS

Gastroenterology ◽

10.1016/s0016-5085(20)34269-4 ◽

2020 ◽

Vol 158 (6) ◽

pp. S-1441

Author(s):

Denise van der Graaff ◽

Wilhelmus J. Kwanten ◽

Benedicte Y. De Winter ◽

Joris De Man ◽

Peter Michielsen ◽

...

Keyword(s):

Vascular Resistance ◽

Liver Damage ◽

Rat Model ◽

Receptor Blocker ◽

Angiotensin Receptor ◽

Intrahepatic Vascular Resistance

Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan

International Journal of Molecular Medicine ◽

10.3892/ijmm_00000075 ◽

1998 ◽

Cited By ~ 1

Author(s):

Morishita

Keyword(s):

Abdominal Aortic Aneurysm ◽

Aortic Aneurysm ◽

Rat Model ◽

Receptor Blocker ◽

Angiotensin Receptor ◽

Abdominal Aortic

Synergistic protective effects of a statin and an angiotensin receptor blocker for initiation and progression of atherosclerosis

PLoS ONE ◽

10.1371/journal.pone.0215604 ◽

2019 ◽

Vol 14 (5) ◽

pp. e0215604 ◽

Cited By ~ 2

Author(s):

Seul-Gee Lee ◽

Seung-Jun Lee ◽

Nguyen Viet Phuong Thuy ◽

Jung-Sun Kim ◽

Jung-Jae Lee ◽

...

Keyword(s):

Receptor Blocker ◽

Protective Effects ◽

Angiotensin Receptor ◽

Progression Of Atherosclerosis

Fimasartan, a new angiotensin receptor blocker, normalized vascular calcification in medial elastocalcinosis rat model

International Journal of Cardiology ◽

10.1016/j.ijcard.2011.08.700 ◽

2011 ◽

Vol 152 ◽

pp. S70

Author(s):

Jeong Bae Park ◽

Young Mee Park

Keyword(s):

Vascular Calcification ◽

Rat Model ◽

Receptor Blocker ◽

Angiotensin Receptor Blocker ameliorates hyperlipidemia and increases lipid utilization in a rat model of metabolic syndrome

The FASEB Journal ◽

10.1096/fasebj.30.1_supplement.1292.13 ◽

2016 ◽

Vol 30 (S1) ◽

Author(s):

Jose Antonio Garcia ◽

Andrew Lee ◽

Rudy Ortiz

Keyword(s):

Metabolic Syndrome ◽

Rat Model ◽

Receptor Blocker ◽

Angiotensin Receptor ◽

Lipid Utilization

555 Indirect comparison of the effects of adding an aldosterone antagonist or an angiotensin receptor blocker in severe heart failure: new data from the CHARM-Added trial

European Journal of Heart Failure Supplements ◽

10.1016/s1567-4215(06)80352-8 ◽

2006 ◽

Vol 5 (1) ◽

pp. 124-124

Author(s):

R WEIR ◽

J MCMURRAY ◽

C GRANGER ◽

B OLOFSSON ◽

J OSTERGREN ◽

...

Keyword(s):

Heart Failure ◽

Indirect Comparison ◽

Severe Heart Failure ◽

Receptor Blocker ◽

Angiotensin Receptor ◽

Aldosterone Antagonist